45 related articles for article (PubMed ID: 23370426)
1. Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.
Schildgen V; Lüsebrink J; Appel JD; Wübben C; Engel-Riedel W; Ludwig C; Stoelben E; Schildgen O; Brockmann M
Diagn Mol Pathol; 2013 Mar; 22(1):22-7. PubMed ID: 23370426
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
3. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
Harlé A; Lion M; Lozano N; Husson M; Harter V; Genin P; Merlin JL
Oncol Rep; 2013 Mar; 29(3):1043-52. PubMed ID: 23314198
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J
Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
Kozaki K; Imoto I; Pimkhaokham A; Hasegawa S; Tsuda H; Omura K; Inazawa J
Cancer Sci; 2006 Dec; 97(12):1351-8. PubMed ID: 17052259
[TBL] [Abstract][Full Text] [Related]
6. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Hafner C; Landthaler M; Vogt T
Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
[TBL] [Abstract][Full Text] [Related]
8. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA Mutations in Resected Small Cell Lung Cancer.
Han N; Cheng QY; Chen B; Cai JF; Wang XJ; Lou CJ; Qin J; Ye WW; Lei L; Lu HY
Adv Clin Exp Med; 2016; 25(3):397-402. PubMed ID: 27629725
[TBL] [Abstract][Full Text] [Related]
10. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
[TBL] [Abstract][Full Text] [Related]
11. Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer.
Akca H; Demiray A; Yaren A; Bir F; Koseler A; Iwakawa R; Bagci G; Yokota J
Cancer Genet; 2013 Mar; 206(3):73-80. PubMed ID: 23491080
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
McIntyre JB; Wu JS; Craighead PS; Phan T; Köbel M; Lees-Miller SP; Ghatage P; Magliocco AM; Doll CM
Gynecol Oncol; 2013 Mar; 128(3):409-14. PubMed ID: 23266353
[TBL] [Abstract][Full Text] [Related]
13. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
[TBL] [Abstract][Full Text] [Related]
14. Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
Ismail SI; Mahmoud IS; Msallam MM; Sughayer MA
Leuk Res; 2010 Jun; 34(6):824-6. PubMed ID: 20022634
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutations predict local recurrences in rectal cancer patients.
He Y; Van't Veer LJ; Mikolajewska-Hanclich I; van Velthuysen ML; Zeestraten EC; Nagtegaal ID; van de Velde CJ; Marijnen CA
Clin Cancer Res; 2009 Nov; 15(22):6956-62. PubMed ID: 19903786
[TBL] [Abstract][Full Text] [Related]
16. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
Massion PP; Taflan PM; Shyr Y; Rahman SM; Yildiz P; Shakthour B; Edgerton ME; Ninan M; Andersen JJ; Gonzalez AL
Am J Respir Crit Care Med; 2004 Nov; 170(10):1088-94. PubMed ID: 15317667
[TBL] [Abstract][Full Text] [Related]
17. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
[TBL] [Abstract][Full Text] [Related]
18. Molecular spectrum of PIK3CA gene mutations in patients with nonsmall-cell lung cancer in Turkey.
Ekinci S; Ilgin-Ruhi H; Dogan M; Gursoy S; Dizbay-Sak S; Demirkazik A; Tukun A
Genet Test Mol Biomarkers; 2015 Jul; 19(7):353-8. PubMed ID: 26053643
[TBL] [Abstract][Full Text] [Related]
19. A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.
Penson RT; Sales E; Sullivan L; Borger DR; Krasner CN; Goodman AK; del Carmen MG; Growdon WB; Schorge JO; Boruta DM; Castro CM; Dizon DS; Birrer MJ
Gynecol Oncol; 2016 Apr; 141(1):108-12. PubMed ID: 27016236
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations in small bowel adenocarcinoma.
Shenoy S
Tumori; 2015 Jun; 101(3):e85-7. PubMed ID: 25908046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]